State of New Jersey Common Pension Fund D Has $3.27 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

State of New Jersey Common Pension Fund D grew its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 10.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 71,013 shares of the biopharmaceutical company’s stock after buying an additional 6,559 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Xenon Pharmaceuticals were worth $3,271,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Arizona State Retirement System grew its position in Xenon Pharmaceuticals by 2.2% in the 3rd quarter. Arizona State Retirement System now owns 14,478 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 313 shares during the last quarter. Barclays PLC lifted its holdings in shares of Xenon Pharmaceuticals by 3.7% during the 3rd quarter. Barclays PLC now owns 9,521 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 342 shares during the period. Alps Advisors Inc. lifted its holdings in shares of Xenon Pharmaceuticals by 1.3% during the 3rd quarter. Alps Advisors Inc. now owns 47,349 shares of the biopharmaceutical company’s stock worth $1,617,000 after acquiring an additional 626 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of Xenon Pharmaceuticals by 22.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 3,967 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 720 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Xenon Pharmaceuticals by 5.5% during the 3rd quarter. Teacher Retirement System of Texas now owns 14,418 shares of the biopharmaceutical company’s stock worth $493,000 after acquiring an additional 746 shares during the period. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Stock Up 1.0 %

Shares of XENE opened at $40.50 on Friday. Xenon Pharmaceuticals Inc. has a twelve month low of $27.99 and a twelve month high of $50.99. The firm’s 50 day moving average price is $43.95 and its two-hundred day moving average price is $41.04.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.12. During the same quarter in the prior year, the business posted ($0.57) earnings per share. Xenon Pharmaceuticals’s revenue was up .0% on a year-over-year basis. On average, equities analysts forecast that Xenon Pharmaceuticals Inc. will post -3.04 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on XENE shares. Needham & Company LLC reaffirmed a “buy” rating and set a $62.00 price objective on shares of Xenon Pharmaceuticals in a report on Friday, April 12th. Citigroup began coverage on shares of Xenon Pharmaceuticals in a research report on Thursday, January 4th. They set a “buy” rating and a $62.00 price target for the company. Wedbush boosted their price objective on shares of Xenon Pharmaceuticals from $46.00 to $51.00 and gave the company an “outperform” rating in a report on Friday, March 1st. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, April 10th. Finally, Bank of America boosted their price objective on shares of Xenon Pharmaceuticals from $52.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $59.44.

Insider Transactions at Xenon Pharmaceuticals

In other news, EVP Sherrington Robin sold 7,137 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $330,300.36. Following the sale, the executive vice president now owns 8,398 shares of the company’s stock, valued at $388,659.44. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Steven Gannon sold 13,000 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.28, for a total value of $601,640.00. Following the sale, the director now owns 2,000 shares of the company’s stock, valued at $92,560. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Sherrington Robin sold 7,137 shares of the business’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $46.28, for a total transaction of $330,300.36. Following the completion of the sale, the executive vice president now directly owns 8,398 shares in the company, valued at approximately $388,659.44. The disclosure for this sale can be found here. 5.43% of the stock is currently owned by insiders.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.